For founders building in GLP-1 weight loss, TRT, hormone therapy, peptides, hair loss, or sexual health, the pitch is appealing: plug into an existing network, use a ready platform, access providers and pharmacy fulfillment, and get to market in weeks instead of building the entire clinical infrastructure from scratch. White label telehealth can be a smart way to launch quickly and that speed can be valuable, especially in the early stage. The problem is not the white label model itself. The problem is signing a white label telehealth agreement that quietly makes it expensive, slow, or contractually difficult to later move into your own MSO/PC structure.
For many telehealth founders, the long-term goal is not to stay dependent on someone else’s network forever. The goal is often to use a white label telehealth platform as a bridge while the business validates demand, grows revenue, and prepares for a more durable MSO/PC model. Whether that path stays open depends on the contract you sign at the beginning.
Not All White Label Telehealth Networks Are the Same
Before reviewing the contract traps, founders need to understand what they are actually buying. The phrase “white label telehealth network” is often used broadly, but the legal and exit consequences are different depending on the model.
A pure technology platform gives you the software layer. That may include intake forms, an EHR, patient or order management, billing rails, and pharmacy integrations. These platforms typically do not employ or contract the doctors, and the agreements often make clear that the platform is not acting as a pharmacy or healthcare provider. In that structure, you still need to source clinical coverage separately, either through another medical network or your own PC. Leaving is usually more of a technology and data migration issue than a clinical relationship issue, assuming the data and IP terms allow it.
A technology platform with an affiliated medical network is different. In that model, the company you contract with may provide the platform and route clinical services through one or more affiliated professional entities, plus pharmacy partners. The vendor has effectively built the type of MSO/PC structure you may eventually want, but you are renting access to it rather than owning it. The clinical relationship, medical records, provider-patient relationship, and prescribing sit with their PC, not yours.
Some vendors are the medical network itself. These are provider organizations or affiliated professional entities that make licensed providers available through your platform, often for a recurring network access fee plus per-consult fees. In these arrangements, the provider-patient relationship and medical records typically belong to the network’s professional entities. Leaving can mean rebuilding clinical coverage state by state.
There are also conduit network access models, where a company gives you access to a platform and a network of contracted physicians, sometimes while reserving broad rights to substitute, modify, or discontinue services or fees. In those structures, you may be even further removed from the clinicians, and the clinical relationship still lives with the network.
The key question is simple: if you want to build your own MSO/PC in 18 months, or operate one alongside the white label network, what in the contract stops you, slows you down, or charges you for doing it?
Why the MSO/PC Path Matters
Many serious telehealth companies eventually move toward a friendly-PC/MSO model because it gives the business more durable control over the brand, operations, and economics while respecting legal limits around the practice of medicine. In many states, corporate practice of medicine rules restrict general business corporations from employing physicians or owning a medical practice. A professional corporation owned by licensed professionals handles the clinical side, while the MSO provides management, technology, marketing, and administrative services under a management services agreement.
Fee-splitting laws also matter. Many states prohibit splitting professional fees with non-licensees, which is why white label arrangements often use fixed technology or management fees set at fair market value instead of a percentage of clinical revenue.
Federal anti-kickback law and EKRA can also affect how money moves when payments could be viewed as tied to referrals. Cash-pay design, fixed fair market value fees, and language stating that compensation is not based on the volume or value of referrals often come from this compliance framework.
White label networks can let founders defer building all of this themselves. But if the long-term plan is to graduate into your own MSO/PC, the white label contract should function as a stepping stone, not a cage.
Contract Trap #1: Term, Auto-Renewal, and Termination Rights
One of the first places lock-in appears is the term of the agreement. A founder-friendly structure may be month-to-month with a reasonable notice period. More often, founders see a 12-month initial term with automatic renewal for additional 12-month terms unless notice is given within a specific window, often 30 to 90 days before the current term ends.
That may not sound dangerous until the business misses the notice window and is locked in for another full year. Founders should look for a real termination for convenience right with a reasonable notice period, often 30 to 60 days, along with a non-renewal window that is not overly punitive. A pilot or ramp period with a no-penalty exit can also help the business validate the relationship before committing long term.
If fees were prepaid, the contract should address whether unused fees are refunded if the agreement ends early or if the founder rejects a price increase.
Contract Trap #2: Price Changes and Fee Adjustments
Some white label telehealth agreements give the vendor broad rights to change fees on notice, with continued use treated as acceptance. Some also tie pricing or service availability to regulatory changes. If the vendor can raise prices and the founder’s only option is to leave, the termination language becomes the founder’s leverage. If the termination rights are also tight, the founder may have little practical flexibility.
A better contract gives the business the right to reject a price increase and terminate the affected services without penalty. Founders should also consider fee locks for the initial term, adjustments only at renewal, documented fair market value support, and caps on the size of increases.
Contract Trap #3: Data Ownership and Export Rights
Data is often the quiet exit killer. A founder may assume they can move to their own MSO/PC later, but that becomes difficult if they cannot export the patient list, contact records, transaction history, order data, attribution data, or performance metrics in a usable format.
Some agreements give the vendor broad rights to customer and usage data, including rights that continue after the term ends. Others carve out aggregated data or proprietary platform data as the vendor’s property. Vendors may also exclude pharmacy routing logic, cost basis, margin, formulary cost data, and similar internal platform information from export rights. Some of that is reasonable. A vendor will protect its proprietary platform internals. But founders should draw a clear line around their own commercial and customer data.
A stronger agreement states that the brand owns its commercial data and has the right to export it in CSV or another structured format on request and at termination. It should also restrict the vendor from using customer lists, lead lists, CRM data, campaign data, or attribution data to bypass the brand, solicit its customers outside the program, or redirect patients to vendor-owned brands. Transition cooperation also matters. A 90-day wind-down can help with continuity of care, in-flight orders, data export, and patient-initiated records transfers.
Contract Trap #4: Non-Circumvention, Non-Solicitation, and Provider Contact Bans
The clauses most directly aimed at blocking a future MSO/PC path are often non-circumvention, non-solicitation, and provider-contact restrictions. These provisions may prevent the brand or its affiliates from contacting, soliciting, or doing business outside the platform with pharmacies, provider groups, or clinical contacts introduced through the vendor. Some restrictions may continue for years after termination and may include aggressive damages provisions. The business issue is clear. If the white label network introduces the providers and pharmacies the founder would need for an independent MSO/PC, a broad non-circumvention clause can make that future structure a breach of contract.
Founders should narrow these clauses carefully. Protected relationships should be limited to entities actually and exclusively introduced by the vendor and documented in writing. The restriction should not cover providers or pharmacies the founder already knew, could find through general-market channels, or independently sources later.
The tail should also be reasonable. A shorter period, such as 6 to 12 months, is more workable than a 24-month restriction. Remedies should be tied to a reasonable estimate of harm, not punitive multipliers. Founders should also consider mutual non-circumvention so the vendor cannot use the brand’s funnel to redirect or solicit its customers outside the program.
Most importantly, the contract should preserve the right to build or operate the founder’s own MSO/PC, including a hybrid model alongside the network, as long as the founder does not misuse the vendor’s confidential information.
Contract Trap #5: Exclusivity and “Best Efforts” Platform Commitments
Exclusivity can quietly close off the hybrid path. Some agreements require the brand to use the vendor for all pharmacy management needs, use best efforts to route business through the platform, or obtain consent before expanding services, conditions, states, brands, or supply channels.
Those terms can make it difficult to run an independent MSO/PC for some states or service lines while continuing to use the white label network for others during a transition. A cleaner agreement is non-exclusive. It should allow each party to work with others and should preserve the founder’s right to operate parallel clinical arrangements, including its own PC. “All needs” or “best efforts” obligations should be replaced with narrower, non-exclusive commitments.
Contract Trap #6: Service Changes and Vendor Discretion
Some agreements allow the vendor to substitute, modify, or discontinue services, fees, platform features, SKUs, or formulary items with little or no notice. If a vendor can remove a medication, state, or feature your business depends on, the contract needs a practical remedy.
Founders should look for advance notice of material changes and a termination right if the change materially impairs the program. Service-level commitments, support response times, credits, and tolling of minimums during vendor-caused outages can also matter.
Contract Trap #7: Compliance Architecture
A white label telehealth structure should be built to comply with AKS, EKRA, corporate practice of medicine rules, and fee-splitting laws. Stronger agreements often include cash-pay-only restrictions, fixed fees set in advance at fair market value, compensation that is not based on the volume or value of referrals, and clear allocation of clinical decision-making to licensed providers.
Founders should confirm that fees are fixed and fair market value supported, not a percentage of clinical revenue and not tied to prescribing volume, dosage, or fill quantity. The agreement should also clearly separate clinical and commercial roles. Providers should control clinical decisions, records, and the provider-patient relationship, while the brand controls marketing, retail pricing discretion, and the commercial side of the business.
Indemnification should match control. Clinical, pharmacy, and controlled-substance compliance risk should sit with the party that controls that area, not automatically with the consumer-facing brand. A change-in-law provision and a good-faith renegotiation process can also help if the structure needs to be adjusted to remain compliant.
A Practical Pre-Signing Checklist
Before signing a white label telehealth agreement, founders should be able to answer these questions:
- What model is this really: pure technology, technology plus affiliated PC, the medical network itself, or a conduit network access model?
- Can the business leave on reasonable notice without penalty?
- Can the business export patient and customer data in a usable format?
- Can the vendor use the brand’s data to compete with it?
- Do the non-circumvention or non-solicitation terms block a future MSO/PC or hybrid model?
- Is the business locked into exclusivity or an “all needs” commitment?
- Is the compliance structure built around AKS, EKRA, CPOM, and fee-splitting requirements?
- Is the brand indemnified for areas it does not control?
- What happens operationally when the brand decides to go independent?
Unfavorable answers do not always mean the founder should walk away. They do mean the founder should negotiate and price the lock-in into the deal.
FAQ
What is a white label telehealth platform?
A white label telehealth platform may provide software such as intake flows, EHR tools, patient or order management, billing rails, and pharmacy integrations. Some platforms are technology-only, while others are connected to affiliated medical networks.
Why do telehealth founders move from white label telehealth to an MSO/PC?
Many founders eventually want more durable control over the clinical brand, economics, operations, and long-term structure while still respecting corporate practice of medicine and fee-splitting rules.
What contract terms can block a future MSO/PC structure?
Terms that can create lock-in include long auto-renewals, weak termination rights, broad price-change rights, unclear data export rights, non-circumvention clauses, provider-contact bans, exclusivity provisions, and broad vendor discretion to change services.
Can a white label telehealth agreement support a hybrid model?
It can, but only if the agreement preserves the right to operate parallel clinical arrangements, including the founder’s own PC, and does not require exclusivity or all-needs commitments.
LumaLex Law’s Bottom Line
White label medical networks can be a legitimate and useful way to launch a telehealth brand without immediately building an MSO/PC. The risk is signing terms that turn a temporary bridge into a permanent dependency.
The provisions that matter most are term and termination, fee changes, data ownership and export, non-circumvention, provider solicitation, exclusivity, service discretion, and compliance architecture. Those terms determine whether the business can eventually move into its own MSO/PC structure, operate a hybrid model, or remain dependent on the vendor longer than expected.
Negotiate the exit path before you sign, not after the vendor has your patient base.
Talk to LumaLex Law About White Label Telehealth Agreements
LumaLex Law advises telehealth founders and healthcare businesses on white label telehealth agreements, MSO/PC strategy, contract structure, and emerging healthcare compliance issues.
If you are evaluating a white label telehealth platform or preparing to build your own MSO/PC structure, Schedule a consultation with us to discuss the contract terms before you sign.
Disclaimer: This article is provided for general informational purposes only and does not constitute legal advice or create an attorney-client relationship. Telehealth and healthcare rules vary by state and change frequently. Consult qualified counsel about your specific facts.
